Redefining prenatal testing through metabolomics-driven innovation
Precizioniq is pioneering accessible and affordable non-invasive diagnostics that enable the early detection of prenatal chromosomal abnormalities such as Down and Turner syndromes. By identifying key biomarkers from blood and urine as early as 6 weeks, we empower timely clinical decisions and the potential to transform outcomes for millions of women.
US $250,000 from an angel investor
One comprehensive provisional patent filed with the Indian Patent Office for our metabolomics-based prenatal diagnostic platform.
We are in the final due-diligence stage of a major government grant.
Five team members, former researchers from Cornell, Baylor College of Medicine, and UC.
Co-Founder & CTO
Co-Founder & CSO
Co-Founder & CEO
Co-Founder & COO
Co-Founder & CGO
